echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Eur J Cancer: Long-term efficacy of Bona Twain anti-anti-treatment in patients with relapsed/refraction Philadelphia chromosome-positive ALL

    Eur J Cancer: Long-term efficacy of Bona Twain anti-anti-treatment in patients with relapsed/refraction Philadelphia chromosome-positive ALL

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Philadelphia (Ph) chromosomes with t (9; 22)(q34; q11) subseign is characterized by the most common cytogenetic abnormality in patients with acute lymphoblastic leukemia (ALL).
    about 25% of adult ALL patients with B-cell pregeners (BCP) have Ph chromosomal-positive (Ph-plus), characterized by the formation of the BCR-ABL1 fusion gene on Ph chromosomes.
    Bonatumomab is a dual-specific CD19 CD3 T cell bridger that binds to CD19 on the surface of B cells and CD3 on the surface of T cells to connect T cells to malignant B cells to activate endogenetic T cells, thus acting as an anti-tumor. the
    Study FlowChart ALCANTARA study is a multicenter, open-label Phase 2 one-arm trial that includes patients with relapses over the age of 18 or at least one TKI refractic Ph-ALL, with the aim of assessing the long-term durability of Bonathumab for use in such patients.
    end point is to achieve full remission (CR)/full remission (CR) and partial hematological recovery (CRh) in the first two courses of Bona Tso monotherapy.
    non-recurrence survival rate this analysis included 45 patients who completed the study between January 3, 2014 and January 6, 2017, 16 of whom (35.6%; 95% CI 21.9%-51.2%) obtained CR/CRh in the first two Bonatho monotherapy sessions.
    16.1 months after the medium total survival rate, the medium recurrence period (RFS) was 6.8 months (95% CI 4.4 months - not reached.
    25.1 months of medium follow-up, the total lifetime (OS) was 9.0 months (95% CI 5.7-13.5).
    the remission duration of CR patients with MRD full responders was significantly longer than in non-CR patients (19.8 vs 6.0 months).
    of the 16 patients who received CR/CRh, 14 received complete remission of micro-residual lesions (MRD), with a medium duration of 9.7 months (95% CI 5.2-NE).
    treatment-related adverse events are consistent with previous reports.
    , patients with R/R Ph-ALL had long-lasting responses to Bonatho monoantigen.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.